BioSpace News Archive

As the COVID-19 pandemic began, our priority was to make sure that our employees were safe and that we took the necessary measures to protect our supply chain operations, which have enabled us to continue to fulfill our mission of improving people’s lives with our health care products

Pear Therapeutics, Inc., the leader in prescription digital therapeutics, announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Bank of America Merrill Lynch 2020 Virtual Healthcare Conference on Thursday, May 14 at 2:20 p.m. Eastern Time.

Sierra Oncology, Inc. (SRRA), today reported its financial and operational results for the first quarter ending March 31 2020

- Agreement enables Caribou to utilize MaxCyte’s ExPERT® platform for its CRISPR gene-edited, allogeneic T cell therapy programs

Bicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Apellis Pharmaceuticals , Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had entered into subscription agreements with a number of institutional investors for a private placement of $300.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”) for an aggregate purchase price of $328.9 million. The private placement is expected to close on May

resTORbio, Inc., a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020

ADMA Biologics, Inc. announced several recent corporate achievements pertaining to its supply chain robustness objectives as established at the beginning of 2020.

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.